04:38:38 PM

NXTC Stock News

NXTC - Nextcure Inc

06/27/22 8:00 AM

Nasdaq : NXTC

low float

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ECM

RHEA-AI

neutral

06/22/22 8:00 AM

Nasdaq : NXTC

managementclinical triallow float

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting

RHEA-AI

neutral

06/08/22 8:00 AM

Nasdaq : NXTC

conferenceslow float

NextCure to Present at the JMP Securities Life Sciences Conference

RHEA-AI

neutral

05/05/22 4:05 PM

Nasdaq : NXTC

earningslow float

NextCure Provides Business Update and Reports First Quarter 2022 Financial Results

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : NXTC

conferenceslow float

NextCure to Present at the BofA Securities 2022 Healthcare Conference

RHEA-AI

neutral

04/19/22 7:30 AM

Nasdaq : NXTC

clinical triallow float

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

RHEA-AI

neutral

04/05/22 8:00 AM

Nasdaq : NXTC

conferenceslow float

NextCure to Present at 21st Annual Needham Virtual Healthcare Conference

RHEA-AI

neutral

03/03/22 4:05 PM

Nasdaq : NXTC

earningslow float

NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

NextCure, Inc. (Nasdaq: NXTC), a

RHEA-AI

neutral

02/08/22 8:00 AM

Nasdaq : NXTC

conferenceslow float

NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

RHEA-AI

neutral

12/13/21 8:05 AM

Nasdaq : NXTC

low float

NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

RHEA-AI

neutral

1 2 3 4 5 Next

NXTC Data

Websitewww.nextcure.com
Security nameNextcure Inc
Issue typecs
Sic code2834
Employees90
Tags
- Biotechnology
- Health Technology
Address9000 Virginia Manor Rd Ste 200
StateMaryland
CityBeltsville
Zip20705-4214
CountryUS
Phone12403994900

About Nextcure Inc

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.